News and Announcements
Clevertar funding round half filled
- Published May 04, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Clevertar is pleased to announce recent capital raising success.
- This round positions Clevertar to both develop its platform and expand its market reach.
Virtual assistant platform provider Clevertar, is pleased to announce recent capital raising success, in attracting $1m under its current round targetting up to $2m. Mark Pitcher, MD said that, “We’re very pleased with this result; Clevertar’s offering is highly scalable and within a technology area predicted to grow tenfold over the next 5 years. This round positions Clevertar to both develop its platform and expand its market reach and we look forward to doing so”. Originally based on university research, Clevertar brings ‘virtual guides’ to life, allowing enterprises to deliver influential and engaging programs to their consumers directly via the Clevertar platform. Clevertar is already in use in multiple health applications, and its customer pipeline demonstrates its wide applicability in health and beyond. Clevertar’s platform is available at www.clevertar.com.
About Clevertar Pty Ltd
Clevertar is an award-winning Australian technology company that brings behaviour changing ‘relational agents’ to healthcare. It has developed a SaaS platform for deployment of a range of digital coaches, which already includes coaches for type 2 diabetes, mental health, chronic pain and chronic heart failure.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
